Posted by Michael Wonder on 19 Sep 2017
U.S. FDA approves new indication for Ipsen’s Somatuline Depot (lanreotide) injection for the treatment of carcinoid syndrome
18 September 2017 - Ipsen today announced that the U.S. FDA has approved a supplemental indication for Somatuline Depot (lanreotide) injection 120 mg for the treatment of carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analogue rescue therapy.
Somatuline Depot is also approved for the improvement of progression-free survival in patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastro-enteropancreatic neuroendocrine tumours.
The additional Somatuline Depot approval for carcinoid syndrome was based on “Evaluation of Lanreotide Depot/Autogel Efficacy and Safety as a Carcinoid Syndrome Treatment (ELECT): A Randomized, Double-Blind, Placebo-Controlled Trial,” published in Endocrine Practice.
